Frailty and outcomes in adults undergoing systemic anticancer treatment: a systematic review and meta-analysis
Gebrechlichkeit und Outcomes bei Erwachsenen unter systemischer Antikrebstherapie: systematische Übersicht und Metaanalyse
JNCI: Journal of the National Cancer Institute · 01.07.2025 · 117 (7) · 1316-1339
DOI: 10.1093/jnci/djaf017 ↗Auf einen Blick
Die Übersichtsarbeit zeigt: Prätherapeutische Gebrechlichkeit war bei Erwachsenen mit Krebs mit ungünstigeren Outcomes unter systemischer Antikrebstherapie verbunden. Besonders prognostisch waren Geriatric-8 und Vulnerable Elders Survey-13.
Fragestellung
Welche Assoziation besteht zwischen baseline Gebrechlichkeit und Outcomes unter systemischer Antikrebstherapie bei Erwachsenen mit Krebs?
Methode
Systematische Suche in 5 Datenbanken bis Januar 2023; prognostische Faktorenstudien mit validierter Frailty-Erhebung vor Behandlung bei Erwachsenen mit soliden Tumoren; Biasbewertung mit QUIPS.
Ergebnisse
58 Studien. Gepoolt war Gebrechlichkeit mit höherer Mortalität (HR 1,68; 95 %-KI 1,41–2,00), Toxizität (OR 1,83; 95 %-KI 1,24–2,68), Therapieunverträglichkeit (OR 1,68; 95 %-KI 1,32–2,12) und Hospitalisierung (OR 1,94; 95 %-KI 1,32–2,83) verbunden.
Einschränkungen
Die Studien betrafen unterschiedliche Tumorarten; die meisten Einschlussstudien waren in älteren Patient:innen und in fortgeschrittener bzw. palliativer Situation.
Schlussfolgerung der Autor:innen
Einfache, kurze Frailty-Assessments einschließlich Geriatric-8 und Vulnerable Elders Survey-13 sind prognostisch für wichtige Outcomes unter systemischer Antikrebstherapie und sollen die gemeinsame Entscheidungsfindung unterstützen.
Kernaussagen
- Frailty war mit höherer Mortalität verbunden
- Auch Toxizität, Unverträglichkeit und Hospitalisierung nahmen zu
- Geriatric-8 und VES-13 zeigten prognostische Aussagekraft
Deutsche Zusammenfassung: KI-gestützt aus dem Original-Abstract erstellt; alle Zahlen wurden automatisch mit dem Original abgeglichen. Maßgeblich ist der Original-Abstract.
Kurz gefasst
Systematische Übersicht in der Zeitschrift JNCI: Journal of the National Cancer Institute, online erschienen am 30.01.2025. Verfasst von Jessica Pearce und 10 weiteren Autor:innen. Beteiligte Einrichtung: Leeds Institute of Medical Research at St James's, University of Leeds, Leeds LS2 9JT, United Kingdom. Hauptthemen laut MEDLINE: Antineoplastic Agents, Frailty, Neoplasms. Die Arbeit wurde bisher 51-mal zitiert (Crossref) und nennt 112 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Institute for Health Research, Core Clinical Trials Unit Infrastructure, Cancer Research UK.
Themen: Gerontologische Pflege
Abstract (Originalsprache)
Background
It is increasingly recognized that frailty should be assessed and considered in treatment decision making in patients with cancer. This review and meta-analysis synthesizes existing evidence evaluating the association between baseline frailty and systemic anticancer treatment outcomes in adults with cancer.
Methods
Five databases were systematically searched from database inception to January 2023 to identify prognostic factor studies (cohort or case-control design) reporting the associations between validated frailty assessments (pretreatment) and follow-up outcomes in adults with solid-organ malignancy undergoing systemic anticancer treatment. Risk of bias was assessed via Quality of Prognosis Studies in Systematic Reviews tool. Where appropriate, associations between frailty and outcomes (survival, toxicity, treatment tolerance, functional decline/quality of life, and hospitalization) were synthesized in meta-analysis and presented as forest plots.
Results
A total of 58 studies met inclusion criteria. They were undertaken in a range of tumor sites and mainly in older patients and advanced and/or palliative disease settings. Most had low or moderate risk of bias. Nine frailty assessment tools were evaluated. Four outcomes were synthesized in meta-analysis, which demonstrated the prognostic value of 2 tools: Geriatric-8 (survival, treatment tolerance, hospitalization) and Vulnerable Elders Survey-13 (survival, toxicity, treatment tolerance). Overall pooled estimates indicate that frailty conveys an increased risk of mortality (hazard ratio [HR] = 1.68, 95% confidence interval [CI] = 1.41 to 2.00), toxicity (odds ratio [OR] 1.83, 95% CI = 1.24 to 2.68), treatment intolerance (OR = 1.68, 95% CI = 1.32 to 2.12), and hospitalization (OR = 1.94, 95% CI = 1.32 to 2.83).
Conclusion
Simple, brief frailty assessments including Geriatric-8 and Vulnerable Elders Survey-13 are prognostic for a range of important outcomes in patients undergoing systemic anticancer treatment. Risk estimates should be used to support shared decision making.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Leeds Institute of Medical Research at St James's, University of Leeds, Leeds LS2 9JT, United Kingdom.
- Leeds Institute of Oncology, Leeds Teaching Hospitals National Health Service Trust, Leeds LS9 7TF, United Kingdom.
- Royal Papworth Hospital National Health Service Foundation Trust, Cambridge CB2 0AY, United Kingdom.
- Academic Cancer Sciences Unit, University of Southampton, Southampton SO16 6YD, United Kingdom.
- Department of Oncology, Cambridge University Hospitals, University of Cambridge, Cambridge CB2 0SP, United Kingdom.
- Clinical Oncology, The Christie National Health Service Foundation Trust, Manchester M20 4BX, United Kingdom.
ORCID-Profile: Jessica Pearce, Sally Martin, Sophie Heritage, Emma G Khoury, Joanna Kucharczak, Thitikorn Nuamek, David A Cairns, Galina Velikova, Suzanne H Richards, Andrew Clegg, Alexandra Gilbert
Förderung
- National Institute for Health Research
- Core Clinical Trials Unit Infrastructure
- Cancer Research UK
Zitieren
APA
Pearce, J., Martin, S., Heritage, S., Khoury, E. G., Kucharczak, J., Nuamek, T., Cairns, D. A., Velikova, G., Richards, S. H., Clegg, A., & Gilbert, A. (2025). Frailty and outcomes in adults undergoing systemic anticancer treatment: a systematic review and meta-analysis. JNCI: Journal of the National Cancer Institute, 117(7), 1316-1339. https://doi.org/10.1093/jnci/djaf017
Vancouver
Pearce J, Martin S, Heritage S, Khoury EG, Kucharczak J, Nuamek T, et al. Frailty and outcomes in adults undergoing systemic anticancer treatment: a systematic review and meta-analysis. JNCI: Journal of the National Cancer Institute. 2025;117(7):1316-1339. doi:10.1093/jnci/djaf017
BibTeX
@article{Pearce2025,
author = {Pearce, Jessica and Martin, Sally and Heritage, Sophie and Khoury, Emma G and Kucharczak, Joanna and Nuamek, Thitikorn and Cairns, David A and Velikova, Galina and Richards, Suzanne H and Clegg, Andrew and Gilbert, Alexandra},
title = {Frailty and outcomes in adults undergoing systemic anticancer treatment: a systematic review and meta-analysis},
journal = {JNCI: Journal of the National Cancer Institute},
year = {2025},
volume = {117},
number = {7},
pages = {1316--1339},
doi = {10.1093/jnci/djaf017}
}
EUVIMED